Markets and Product Pipeline Overview

Tolera plans to develop and commercialize therapies for the immune suppression and immune modulation markets; to address unmet medical needs with safer, targeted solutions. These markets include segments such as autoimmune disease and transplantation. Currently available therapies often carry significant risk of serious and toxic side effects. As a result, physicians are seeking novel and safer solutions for their patients.

Tolera’s initial focus will be to commercialize its therapeutic monoclonal antibody for the transplantation and autoimmune markets, while researching and developing related therapies to serve patients who will benefit from safer and more targeted immune suppression, or immune modulation. The company owns an exclusive, worldwide license to this therapeutic antibody. The antibody has been the subject of a number of pre-clinical, Phase I, and Phase II trials. Based on this clinical history, the company believes it has a unique opportunity to bring a safer immune therapy to market.

To further enhance the long term value of the pipeline, the company will continue research and development of novel immune modulation discoveries from its scientific collaborators, which offer promise for commercialization of additional novel therapeutics in autoimmune, oncology and transplantation. The company may also seek to in-license additional safer or more effective technologies aimed at these, and other valuable clinical markets.